Cargando…

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

Detalles Bibliográficos
Autores principales:	von Tresckow, Julia, Cramer, Paula, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Fürstenau, Moritz, Illmer, Thomas, Klaproth, Holger, Tausch, Eugen, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Böttcher, Sebastian, Eichhorst, Barbara F., Hallek, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343250/ https://www.ncbi.nlm.nih.gov/pubmed/35752657 http://dx.doi.org/10.1038/s41375-022-01629-7

Ejemplares similares

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
por: Mascolo, Annamaria, et al.
Publicado: (2023)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
por: Schilhabel, Anke, et al.
Publicado: (2022)

Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
por: Agrawal, Rohitashva, et al.
Publicado: (2020)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib
por: Nakhoda, Shazia, et al.
Publicado: (2023)

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020)

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
por: Samineni, Divya, et al.
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
por: Timofeeva, Natalia, et al.
Publicado: (2021)

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
por: Greil, Richard, et al.
Publicado: (2021)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
por: Kutsch, Nadine, et al.
Publicado: (2020)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Davis, Joanne E., et al.
Publicado: (2021)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

From Biology to Therapy: The CLL Success Story
por: Yosifov, Deyan Y., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b1tlf6cosi8hh7nf8sanq43urk